Vitrolife (VITR) Hisse Özeti
Vitrolife AB (publ) Avrupa, Orta Doğu, Afrika, Asya-Pasifik ve Amerika'da yardımcı üreme ürünleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 2/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden VITR için herhangi bir risk tespit edilmedi.
VITR Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vitrolife AB (publ) Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | SEK 90.00 |
| 52 Haftanın En Yüksek Seviyesi | SEK 153.50 |
| 52 Haftanın En Düşük Seviyesi | SEK 84.00 |
| Beta | 1.71 |
| 1 Aylık Değişim | 1.81% |
| 3 Aylık Değişim | -16.59% |
| 1 Yıllık Değişim | -33.58% |
| 3 Yıllık Değişim | -41.63% |
| 5 Yıllık Değişim | -81.20% |
| Halka arzdan bu yana değişim | 1,167.61% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 28
VITR: Leadership Transition And Revised Outlook Will Shape Fairly Balanced Prospects
Analysts have reset their view on Vitrolife with a lower fair value estimate, moving from SEK 141.0 to SEK 95.0. The change reflects updated assumptions on the discount rate, revenue growth, profit margin and future P/E expectations. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role in a different area of the medtech industry.
Anlatı Güncellemesi • Jul 14
VITR: Leadership Transition And Bearish Research Will Set Up Future Re-Rating Potential
Analysts have trimmed their fair value estimate for Vitrolife from SEK162.75 to SEK130.20, citing a slightly higher discount rate, modest adjustments to revenue growth and profit margin assumptions, and more conservative future P/E expectations following recent bearish research and a downgrade. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has resigned to take a CEO role in another part of the medtech industry.
Anlatı Güncellemesi • Jun 30
VITR: Higher Discount Rate Reset Will Likely Unlock Future Upside
The Vitrolife analyst price target has been trimmed from SEK 230 to SEK 215, as analysts cite a higher required discount rate and a lower assumed future P/E multiple following more cautious research, including a downgrade from Pareto. What’s in the News for Vitrolife Vitrolife AB (publ) announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role elsewhere in the medtech industry.Anlatı Güncellemesi • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.Recent updates
Anlatı Güncellemesi • Jul 28
VITR: Leadership Transition And Revised Outlook Will Shape Fairly Balanced Prospects
Analysts have reset their view on Vitrolife with a lower fair value estimate, moving from SEK 141.0 to SEK 95.0. The change reflects updated assumptions on the discount rate, revenue growth, profit margin and future P/E expectations. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role in a different area of the medtech industry.Anlatı Güncellemesi • Jul 14
VITR: Leadership Transition And Bearish Research Will Set Up Future Re-Rating Potential
Analysts have trimmed their fair value estimate for Vitrolife from SEK162.75 to SEK130.20, citing a slightly higher discount rate, modest adjustments to revenue growth and profit margin assumptions, and more conservative future P/E expectations following recent bearish research and a downgrade. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has resigned to take a CEO role in another part of the medtech industry.Anlatı Güncellemesi • Jun 30
VITR: Higher Discount Rate Reset Will Likely Unlock Future Upside
The Vitrolife analyst price target has been trimmed from SEK 230 to SEK 215, as analysts cite a higher required discount rate and a lower assumed future P/E multiple following more cautious research, including a downgrade from Pareto. What’s in the News for Vitrolife Vitrolife AB (publ) announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role elsewhere in the medtech industry.Anlatı Güncellemesi • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.Anlatı Güncellemesi • Jun 01
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.Anlatı Güncellemesi • May 12
VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential
Vitrolife's analyst price target has been adjusted from SEK 162.67 to SEK 172.20. Analysts point to modest tweaks in fair value assumptions, discount rate, revenue growth, profit margin and future P/E forecasts, even as some research houses, such as Pareto, have turned more cautious on the stock.Anlatı Güncellemesi • Apr 27
VITR: Governance Reforms And Reset Expectations Will Support Future Upside Potential
Vitrolife’s analyst price target has been trimmed slightly from SEK 163.40 to about SEK 162.70, as analysts factor in updated assumptions on growth, margins and future P/E, and reflect the more cautious tone seen in recent research such as Pareto’s downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the revised target near SEK 162.70 as still implying upside relative to where caution has already been factored into growth, margin and P/E assumptions.Anlatı Güncellemesi • Apr 12
VITR: Governance Amendments And Steady Assumptions Will Support Future Upside
Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.Anlatı Güncellemesi • Mar 29
VITR: Stable Fair Value And Tweaked Assumptions Will Support Future Upside
Analysts have kept Vitrolife's fair value estimate broadly unchanged at SEK 176.75, with only minor tweaks to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, which has driven a very small adjustment to their price target framework. Valuation Changes Fair Value Estimate was kept stable at SEK 176.75, indicating no change in the central valuation outcome.Anlatı Güncellemesi • Mar 13
VITR: Genetic Services Restructuring And Impairment Will Underpin Future Upside Potential
Analysts have kept their SEK 176.75 price target for Vitrolife broadly unchanged, making only very small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions to reflect fine tuning in their models rather than a shift in their overall view. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, tied to the Igenomix acquisition (company announcement).Anlatı Güncellemesi • Feb 26
VITR: Genetic Services Restructuring And Impairment Will Support Future Upside Potential
Analysts have left their SEK 176.75 price target for Vitrolife unchanged, with only minimal tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (company announcement).Anlatı Güncellemesi • Feb 11
VITR: Restructuring Of Genetic Services Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife to €176.75 from €187, reflecting updated assumptions that include a higher discount rate, a higher future P/E multiple, and revised expectations for revenue growth and profit margins. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (Key Developments).Anlatı Güncellemesi • Jan 27
VITR: Restructuring And Goodwill Impairment Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife from SEK188.75 to SEK187.00, reflecting adjustments to revenue growth and discount rate assumptions, along with updated views on profit margin and future P/E levels. What's in the News Vitrolife plans a restructuring program for its genetic services business, targeting annualised savings of SEK 65 million.Anlatı Güncellemesi • Jan 10
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Vitrolife at SEK 188.75, with only minor technical adjustments to the discount rate and future P/E assumptions shaping the updated price target narrative. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, related to the Igenomix acquisition (company announcement).Anlatı Güncellemesi • Dec 25
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).Analiz Makalesi • Dec 18
There's No Escaping Vitrolife AB (publ)'s (STO:VITR) Muted Revenues
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a buy right now...Anlatı Güncellemesi • Dec 11
VITR: Higher Long Term Revenue Outlook Will Support Further Upside
Analysts have nudged their price target on Vitrolife slightly higher to SEK 193.50 from SEK 193.00, citing marginally stronger long term revenue growth expectations that more than offset a modest uptick in the assumed discount rate and a slightly lower forecast profit margin. Valuation Changes Fair Value Estimate: unchanged at SEK 193.5 per share, indicating no revision to the intrinsic value despite minor model adjustments.Anlatı Güncellemesi • Nov 27
VITR: Current Metrics And Stable Margins Will Support Further Upside
Analysts have maintained their fair value price target for Vitrolife at SEK 193.50, citing steady expectations for the company's growth, profitability, and valuation metrics. Valuation Changes Consensus Analyst Price Target: Unchanged at SEK 193.50.Analiz Makalesi • Nov 26
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Anlatı Güncellemesi • Nov 11
VITR: Stable Profitability And Marginal Rate Shift Will Drive Future Upside
Narrative Update on Vitrolife Analyst Price Target Vitrolife's analyst price target remains unchanged at SEK 193.50. Analysts cite only minor adjustments in growth and profitability forecasts, affirming their previous valuation stance.Anlatı Güncellemesi • Oct 28
Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead
Narrative Update on Vitrolife Analyst Price Target Analysts have raised Vitrolife’s fair value estimate from SEK191.75 to SEK193.50. They highlight the company's improved profit margin outlook and stronger projected revenue growth as key drivers behind the revised target.Analiz Makalesi • Oct 28
Vitrolife AB (publ) (STO:VITR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Vitrolife AB (publ) ( STO:VITR ) had a good week, as its shares rose 6.6% to close at kr151 following the...Anlatı Güncellemesi • Oct 14
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Analysts have lowered their price target for Vitrolife from SEK 202.50 to SEK 191.75. This reflects updated expectations for slower revenue growth and profit margins, as well as a slightly higher discount rate.Analiz Makalesi • Aug 25
Vitrolife AB (publ)'s (STO:VITR) Shares Lagging The Industry But So Is The Business
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong buy right...Yeni Anlatı • Jul 28
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize.Analiz Makalesi • Jul 08
Vitrolife AB (publ)'s (STO:VITR) Intrinsic Value Is Potentially 68% Above Its Share Price
Key Insights Vitrolife's estimated fair value is kr242 based on 2 Stage Free Cash Flow to Equity Current share price of...Analiz Makalesi • Jun 20
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Apr 25
Vitrolife AB (publ)'s (STO:VITR) Price Is Right But Growth Is Lacking
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.4x might make it look like a buy right now...Analiz Makalesi • Mar 13
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Feb 20
Estimating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr216 based on 2 Stage Free Cash Flow to Equity Vitrolife's kr213...Analiz Makalesi • Nov 27
Is Vitrolife (STO:VITR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Aug 21
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr204 Current share price of...Analiz Makalesi • Jul 20
Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Vitrolife AB (publ) ( STO:VITR ) just released its quarterly report and things are looking bullish. Vitrolife beat...Analiz Makalesi • Jul 18
Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth
The Vitrolife AB (publ) ( STO:VITR ) share price has done very well over the last month, posting an excellent gain of...Analiz Makalesi • Apr 03
Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr215 With kr186 share price...Analiz Makalesi • Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now
The yearly results for Vitrolife AB (publ) ( STO:VITR ) were released last week, making it a good time to revisit its...Analiz Makalesi • Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 62.5x Vitrolife AB (publ) ( STO:VITR ) may be sending very bearish signals...Analiz Makalesi • Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analiz Makalesi • Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr193 based on 2 Stage Free Cash Flow to Equity With kr173 share...Analiz Makalesi • Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Hissedar Getirileri
| VITR | SE Biotechs | SE Pazar | |
|---|---|---|---|
| 7D | 4.5% | -4.2% | 2.4% |
| 1Y | -33.6% | 23.2% | 14.2% |
Getiri vs. Endüstri: VITR geçen yıl % 23.2 oranında getiri sağlayan Swedish Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: VITR geçen yıl % 14.2 oranında getiri sağlayan Swedish Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| VITR volatility | |
|---|---|
| VITR Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 3.3% |
İstikrarlı Hisse Senedi Fiyatı: VITR son 3 ayda Swedish piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: VITR 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1989 | 1,103 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ), Avrupa, Orta Doğu, Afrika, Asya-Pasifik ve Amerika'da yardımcı üreme ürünleri sunmaktadır. Sperm işleme, oosit alma iğneleri, mikromanipülasyon pipetleri, hızlandırılmış sistemler ve değerlendirme araçları, lazer ve görüntüleme sistemleri, IVF ortamı ve yağı, embriyo transferi, kriyoprezervasyon ve genomik kitler sunmaktadır. Şirket ayrıca eWitness ve kaplar, pipetler, tüpler ve VitroTemp gibi Labware ürünleri de sağlamaktadır.
Vitrolife AB (publ) Temel Bilgiler Özeti
| VITR temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | SEK 12.19b |
| Kazançlar(TTM) | -SEK 4.98b |
| Gelir(TTM) | SEK 3.39b |
3.6x
P/S Oranı-2.4x
F/K OranıVITR aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| VITR gelir tablosu (TTM) | |
|---|---|
| Gelir | SEK 3.39b |
| Gelir Maliyeti | SEK 1.38b |
| Brüt Kâr | SEK 2.01b |
| Diğer Giderler | SEK 6.99b |
| Kazançlar | -SEK 4.98b |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
Oct 22, 2026
| Hisse başına kazanç (EPS) | -36.80 |
| Brüt Marj | 59.23% |
| Net Kâr Marjı | -146.99% |
| Borç/Özkaynak Oranı | 18.1% |
VITR uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
1.2%
Mevcut Temettü Verimi-3%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/07 00:39 |
| Gün Sonu Hisse Fiyatı | 2026/08/07 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Vitrolife AB (publ) 11 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | ABG Sundal Collier |
| Kallum Titchmarsh | BofA Global Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |